Billing it­self as the first AI biotech to launch hu­man tri­als, Re­cur­sion adds $121M C round

Billing it­self as the first AI biotech with pro­grams in the clin­ic, Salt Lake City-based Re­cur­sion now has a $121 mil­lion bankroll to start gath­er­ing hu­man da­ta to see if it’s on the right track. 

“We’re try­ing to build this dis­cov­ery en­gine,” Re­cur­sion CEO Chris Gib­son tells me ahead of the C round news. “We now have the first two pro­grams in the clin­ic.” And that, he adds, qual­i­fies as a first for any AI es­tab­lish­ment “that ac­tu­al­ly have some­thing in the clin­ic.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.